ARTICLE | Product Development
Editas, Beam report updates on sickle cell genetic therapies at this year’s ASH meeting
By Lauren Martz, Executive Director, Biopharma Intelligence
December 10, 2024 12:43 AM UTC
In the endeavor to cure sickle cell disease with a one-time genetic treatment, partners Vertex and CRISPR Therapeutics are the field’s leaders, but new data presented at ASH provide early signals that up-and-coming clinical candidates could have the efficacy edge.
It’s been one year since the approvals of the first two genetic medicines for sickle cell disease: Casgevy exagamglogene autotemcel from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and CRISPR Therapeutics AG (NASDAQ:CRSP), and Lyfgenia lovotibeglogene autotemcel from bluebird bio Inc. (NASDAQ:BLUE). …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654414/gene-and-base-editors-deliver-on-fetal-hemoglobin-expression-ash24